-
CStone Announces the Approval of Pujihua(R) (pratinib capsules) in China for the treatment of advanced or metastatic RET-mutant medullary thyroid cancer and RET fusion-positive thyroid cancer
Time of Update: 2022-05-27
Jiang Ningjun, Chairman and Chief Executive Officer of CStone, said: "We are delighted that the expanded indications of Pujihua® have been approved, bringing new treatment options to patients with RET-mutant medullary thyroid cancer and RET fusion-positive thyroid cancer in China.
-
Jinling Pharmaceutical's subsidiary Bangjian Tianfeng Prefilled Catheter Irrigator Approved for Registration
Time of Update: 2022-05-27
Structure and composition/main components: This product is composed of 0.
9% sodium chloride injection, jacket, core rod, cone head cap, and piston .
This product is not suitable for subcutaneous and intramuscular injection .
-
Sanofi and Sobi Announce Long-Acting Hemophilia A Therapy Hits Key Phase 3 Endpoint
Time of Update: 2022-05-27
The study met its primary endpoint, showing a clinically meaningful reduction in bleeding in patients with severe hemophilia A who received once-weekly prophylaxis with efanesoctocog alfa .
At the same time, efanesoctocog alfa showed superiority in preventing bleeding compared with previously received coagulation factor VIII (FVIII) prophylaxis .
-
TOT BIOPHARM's Bevacizumab Injection Approved for Multiple New Indications
Time of Update: 2022-05-27
On March 9, TOT BIOPHARM announced that three new supplementary application indications for bevacizumab injection Puxinting® filed by the company have been approved by the National Medical Products Administration (NMPA), namely: recurrent glioblastoma cell tumors, epithelial ovarian, fallopian tube or primary peritoneal cancer, and cervical cancer .
-
Hengrui Medicine Gadoterate Meglumine Injection passed the consistency evaluation of generic drugs
Time of Update: 2022-05-27
On March 17, 2022, Hengrui Medicine announced that the company's Gadoterate Meglumine Injection has recently received the "Approval Notice for Supplementary Drug Application" approved and issued by th
-
Lingke Pharmaceutical's LNK01001 clinical phase II study completed the first patient dosing
Time of Update: 2022-05-27
On February 28, Lingke Pharmaceutical announced that its selective JAK1 inhibitor LNK01001 for the treatment of autoimmune diseases has completed the first patient dosing in its Phase II clinical trial for Atopic Dermatitis (AD) .
-
All four medicines are reduced in price!
Time of Update: 2022-05-27
On March 8, 2022, Qinghai Province issued a notice to adjust the prices of some medicines .
The notice shows that due to the application of the enterprise, the prices of four drugs, including clarithromycin sustained-release tablets, enme trastuzumab for injection, and enme trastuzumab for injection, will be adjusted .
-
Interim Analysis Shows Positive Efficacy SGLT2 Inhibitor Early Termination of Phase 3 Clinical Trial
Time of Update: 2022-05-27
On March 17, Eli Lilly and Company and Boehringer Ingelheim jointly announced that the SGLT2 inhibitor empagliflozin for the treatment of chronic kidney disease (CKD) patients was based on the recommendation of an independent data monitoring committee.
-
The international clinical trial of innovative drugs is not only "Development" but also "Research"
Time of Update: 2022-05-27
This requires our innovative drug companies to have a sufficiently in-depth understanding of the medical practice of related diseases in the international mainstream (especially the United States), including treatment patterns, patient baselines, and the logic of solving clinical problems .
-
Tianyan Pharmaceutical's Phase Ib/II clinical trial of CTLA-4 mAb combined with pembrolizumab was approved by FDA
Time of Update: 2022-05-27
S. FDA approved Tianyan to conduct a Phase Ib/II new drug clinical trial of its anti-CTLA-4 monoclonal antibody ADG126 and anti-PD-1 antibody pembrolizumab .
ADG126 safe antibody can achieve specific activation in the tumor microenvironment, enhance therapeutic effect through strong clearance of regulatory T cells, and maintain physiological function through flexible ligand blockade .
-
Innovent Biologics/Baoyuan Medicine Talatinib was included in the breakthrough therapy drug category
Time of Update: 2022-05-27
In June 2021, Innovent Bio obtained the rights to jointly develop and commercialize the drug with Baoyuan Pharma in Greater China (including mainland China, Hong Kong, Macau and Taiwan) for a total amount of US$189 million .
-
5 Chinese companies are allowed to produce Pfizer's new crown oral drug Desano for free, and Fosun Pharma is also authorized by Merck & Co.'s Molnupiravir
Time of Update: 2022-05-27
Pfizer Paxlovid authorization mapIn the latest news, the Geneva Medicines Patent Pool (MPP) announced that it has signed agreements with 35 pharmaceutical companies to allow them to produce nirmatrelvir, one of the ingredients of Pfizer’s new crown oral drug Paxlovid .
-
The world's first basal insulin GLP-1RA injection Novozymes(R) launched in China
Time of Update: 2022-05-27
The recently launched Novoyi® (insulin degludec liraglutide injection) is the world's first basal insulin GLP-1RA injection, which is suitable for adult patients with type 2 diabetes with poor blood sugar control.
-
Yisheng Pharmaceutical's ginseng and Shengmai injections are listed in the recommended prescriptions and Chinese patent medicines for critically ill patients
Time of Update: 2022-05-27
On March 17, 2022, Yisheng Pharmaceutical announced that the company's products ginseng and Shengmai injection were included in the "New Coronavirus Pneumonia Diagnosis and Treatment Plan (Trial Version 9)" recommended prescription for critical patients during the clinical treatment period (confirmed cases).
-
Seagen and Sanofi reach cooperation to develop multiple anti-cancer ADCs
Time of Update: 2022-05-27
On March 16, 2022, Seagen and Sanofi announced an exclusive collaboration agreement to design, develop and commercialize antibody drug conjugates (ADCs) against up to three cancer targets .
References:[1] Seagen and Sanofi Announce Collaboration to Develop and Commercialize Multiple Novel Antibody-Drug Conjugates.
-
Online procurement of 3 drugs involves original research, reference preparations and innovative drugs
Time of Update: 2022-05-27
On March 8, 2022, the Shanghai Sunshine Purchasing Network released the first batch of original research/reference preparations/innovative drugs online purchase announcement in 2022 .
16Release date: 2022-03-08Pharmaceutical manufacturers:According to the "Notice on the Full Implementation of the Public Negotiated Procurement of Drugs on the Internet" (Huyaoshi [2018] No.
-
Simcere Pharma and Vivoryon collaborated to target N3pE amyloid protein SIM0408 approved for clinical use
Time of Update: 2022-05-27
SIM0408 is a differentiated oral small molecule investigational drug candidate for Alzheimer's disease with the potential to address multiple key AD pathological mechanisms in a unique mode, including Aβ pathology, neuroinflammation and synaptic damage .
-
Luye Pharma Submits New Drug Application for Lurbinectedin in Hong Kong, China
Time of Update: 2022-05-27
HONG KONG, March 4, 2022 /PRNewswire/ -- Luye Pharma Group announced that its innovative anti-tumor drug, Lurbinectedin, licensed by PharmaMar, has submitted an NDA in Hong Kong, China, for the treatment of patients receiving platinum-based chemotherapy Adult patients with relapsed small cell lung cancer (SCLC) with disease progression during or after the disease .
-
Kintor Pharma Announces Completion of Subject Enrollment in China Phase II Clinical Trial of Furitax for the Treatment of Female Hair Loss
Time of Update: 2022-05-27
For the indication of androgenetic alopecia, on September 8, 2021, Kintor announced that the Phase II clinical trial of furitan for the treatment of male androgenetic alopecia has reached the primary endpoint of the study, and the results show good efficacy and security .
-
Hebo Biopharma's B7-H4/4-1BB bispecific antibody was approved for clinical use in Australia
Time of Update: 2022-05-27
On February 28, Harbin Pharmaceutical announced that IRB approved the application for a Phase I clinical trial of its B7H4/4-1BB bispecific antibody in Australia for patients with solid tumors .
The study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary antitumor activity of HBM7008 in patients with solid tumors .
